About Implantica

Letter from Founder

Letter from Founder

Dear patients, medical practitioners and members of the public:

I take the opportunity to inform you on the founder’s view of the current status of our product development.

From the outset of our activities, our vision was, and continues to be, to make a noticeable contribution to mankind. I dare to claim that the results of our decade of hard work of developing devices how to bring advanced technology into the body, has brought us a long way on our path to fulfilling that vision. We came considerably closer to possibly creating a paradigm shift in MedTech. Today, I am proud to release the results of more than ten years of intensive work within Implantica.

We present our innovative eHealth Wireless Intelligent Energising Platform. Our advanced new system is designed to allow monitoring, energising, controlling and adjusting eHealth devices and smart medical implants wirelessly through intact skin.

We now present our innovative eHealth Wireless Intelligent Energizing Platform, e-InVivo™. Our advanced new system is designed to allow monitoring, energizing, controlling and adjusting eHealth devices and implants wirelessly through intact skin. The key elements of the platform are its security features and advanced feedback system. We believe that our platform may completely change the treatment of many common conditions. We target to launch a number of patented medical implants, allowing the development and production of the next generation of smart medical implants. In the future, healthcare has the potential to be more proactive enabling early detection and monitoring of many different conditions, which will only be possible with advanced technology entering the body.

RefluxStopTM, our device that recently obtained CE mark approval, has the potential to create a paradigm shift in the treatment of acid reflux.

After the successful experience with developing and marketing the Swedish Adjustable Gastric Band (SAGB), the medical implant for treating obesity, which was sold in 2002, we had a vision to take treatment solutions to a new level. RefluxStopTM, our device that recently obtained CE mark approval, has the potential to create a paradigm shift in the treatment of acid reflux. We are focusing on two additional implant products for initial launch, treating urinary incontinence and obesity, each addressing significant market needs. Since the same type of surgeons performs obesity and reflux surgery, we intend to leverage on existing relationships with surgeons from previously selling the SAGB when marketing RefluxStop™ and once again when our future obesity product will be launched.

During the initiated launch process and after having obtained strong clinical trial results, we are focusing on the surgical key opinion leaders from our SAGB contact network. We hope that RefluxStop™ will provide substantial support in the financing of the mid- to long-term development of our product pipeline.

We expect healthcare to take a leap when advanced technology enters the body, in the same way that advanced technology has changed our daily lives.

We expect healthcare to take a leap when advanced technology enters the body, in the same way that advanced technology has changed our daily lives. Our platform technologies and products are designed to bring much-needed relief for suffering individuals, while substantially reducing the economic burden on society.

Yours sincerely,

Peter Forsell
CEO Implantica and Founder
Specialist in General Surgery and Inventor